Abstract A series of 4-(het)aryl-pyrrolo [2,3-d]pyrimidines [6-(het)aryl-7-deazapurine bases] bearing a H, NH 2 , CH 3 , F, or Cl group at the 2-position and either H or F at the 5-position (position 7 of 7-deazapurine) were prepared in a single step by the aqueous SuzukiMiyaura cross-coupling reactions of the corresponding 6-chloro-7-deazapurines with (het)arylboronic acids. Unlike their ribonucleoside derivatives, which are potent cytostatics, the deazapurine bases did not show significant biological activity but most of them exerted bright fluorescence with emission maxima 368-468 nm and high quantum yields up to 0.83. nucleobases, deazapurines, pyrrolo[2,3-d] (7-deazapurines) 1 are an important class of privileged heterocycles and analogues of biogenic purines [for clarity and as reference to the analogy to purines, the (7-deaza)purine nomenclature will be used in the results and discussion, but the correct IUPAC names are given in the experimental section]. Several types of 6-substituted 7-deazapurine bases have been reported to be potent inhibitors of diverse protein kinases.
are an important class of privileged heterocycles and analogues of biogenic purines [for clarity and as reference to the analogy to purines, the (7-deaza)purine nomenclature will be used in the results and discussion, but the correct IUPAC names are given in the experimental section]. Several types of 6-substituted 7-deazapurine bases have been reported to be potent inhibitors of diverse protein kinases. 2 Several recent papers report on the regioselective synthesis of diverse mono-, di-and triaryl-substituted 7-deazapurines, 3 but the synthesis and biological profiling of simple 9-unsubstituted 6-hetaryl-7-deazapurines have not been reported.
In our laboratory, we discovered that the 6-hetaryl-7-deazapurine ribonucleosides 1 and their 7-fluoro congeners 2 (see Figure 1 ) are potent cytostatics 4 and/or inhibitors 5 of mycobacterial adenosine kinase, whereas the 2-substituted derivatives 6 as well as sugar-modified nucleosides 7 were either less active or inactive. On the other hand, the biological activity of the parent deazapurine nucleobases with the same substitution patterns was not known.
Analysis of this class of compound is important for determining the structure-activity relationships because, in principle, the nucleobases could be converted into nucleotides by phosphoribosyl transferases of the salvage pathway. Therefore, we embarked on the synthesis and profiling of two types of 6-(het)aryl-7-deazapurine bases ( Figure 1 ). The first group were the 6-(het)aryl-7-deazapurine derivatives 3 and 4, bearing either H or F at the 7-position, and the second type were 2-substituted 6-hetaryl-7-deazapurine bases 5-9. We were also interested in establishing the photophysical properties of these compounds. For the synthesis of target 6-(het)aryl substituted 7-deazapurines, we intended to use Suzuki-Miyaura crosscoupling reaction under aqueous Shaughnessy conditions, 8 starting from the corresponding 6-chloro-7-deazapurines. We have previously successfully used an analogous methodology for the synthesis of 6-(het)aryl substituted purine bases. 9 The aqueous coupling protocol was versatile and robust and worked even with problematic labile 2-furyl and 2-thienyl boronic acids, which otherwise did not give efficient cross-coupling and had to be replaced by stannanes in the Stille reaction 4,7b or by trifluoroborates in the modified Suzuki reaction. 10 Thus, 6-chloro-7-deazapurine 10 and 6-chloro-7-fluoro-7-deazapurine 11 11 reacted with a series of (het)arylboronic acids to afford the corresponding 6-(het)aryl-7-deazapurine bases 3a-i and 4a-i in one step (Table 1) . Typically, the substrate was treated with boronic acid (1.5 equiv) and Na 2 CO 3 (3 equiv) in the presence of Pd(OAc) 2 (0.05 equiv) and sodium triphenylphosphine trisulfonate (TPPTS) (0.125 equiv) in a water-acetonitrile mixture (2:1) at 100 °C for three hours. The reactions proceeded cleanly with full conversions of starting 6-chloro-7-deazapurines 10 and 11, furnishing the products in high yields. The only exceptions were the 2-and 3-pyrrolyl derivatives (entries 8 and 9), which were obtained in moderate yields. It should also be noted that pyrrole N-protecting groups were cleaved under the reaction conditions (entries 8 and 9). In most cases, the products crystallized nicely from the reaction solvent mixture (except for 2-and 3-pyrrolyl derivatives). However, to obtain even cleaner products, we performed simple chromatography through a short silica gel column to remove precipitated metallic palladium and organic residues arising from the excess of boronic acid. a For R 1 = pyrrol-2-yl, R 2 = N-Boc-1H-pyrrol-2-yl; for R 1 = pyrrol-3-yl, R 2 = N-(triisopropylsilyl)-1H-pyrrol-3-yl. 
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Synthesis of diverse 2-substituted 6-het(aryl) 7-deazapurines 5a-i, 6a-i, 7a-i, and 8a-i was performed by analogous cross-coupling reactions of 2-amino-6-chloro-7-deazapurine 12, 6-chloro-2-methyl-7-deazapurine 13, 12 2-fluoro-6-chloro-7-deazapurine 14 13 and 2,6-dichloro-7-deazapurine 15 (Table 2) . In most cases, the desired 2-substituted 6-hetaryl-7-deazapurine bases were obtained in good to excellent yields (again the pyrrolyl derivatives were prepared less efficiently). It should be noted that no hydrolysis of the relatively reactive 2-fluoro group was observed on 2-fluoro derivatives 7a-f under the basic reaction conditions. In the case of 2,6-dichloro-7-deazapurine 15, some reactions gave, in addition to the desired major 6-monosubstituted products 8, also minor amounts of 2,6-diaryl-7-deazapurines 9b, 9e and 9g, which were easily separated by column chromatography.
Hirao et al. used 6-hetarylpurine nucleosides for the construction of an intrinsically fluorescent unnatural base pair, which was efficiently replicated by polymerases in vitro. 14 We noticed that all final 6-hetaryl-7-deazapurine bases 3-9 exhibited fluorescence; therefore, we studied their photophysical properties in more detail to identify new candidates for the development of fluorescent nucleoside analogues.
We measured UV/Vis absorption and fluorescence spectra of the synthesized compounds in ethanol as model protic solvent. The measured spectroscopic characteristics (absorption coefficients, positions of absorption and emission maxima, quantum yields of fluorescence) are summarized in Table 3 . The studied 7-deazapurine bases bearing aryl and heteroaryl substituents developed a bathochromically shifted band in their UV spectra, which were usually, with a few exceptions, centered between 307 and 363 nm. All studied compounds were substantially fluorescent, exhibiting a single-band emission in the long-UV (blue) range, centered between 368 nm (3i) and 468 nm (5f), as shown in Figure 2 (a). The fluorescence quantum yield of the synthesized compounds ranged from 0.07 for 4d to 0.83 for 7h, with median at 0.43. The variation of the substituents at positions 2 and 7 of the 7-deazapurine core had no apparent effect on the brightness of fluorescence (B = ε max × Φ f ), with the exception of the 7-fluoro series, for which the brightness was relatively low (< 4000 M -1 ·cm
) compared with the other compounds. In contrast, the variation of the aryl and heteroaryl substituents at the 6-position of the 7-deazapurine core had a much stronger effect. Typically, the highest brightness of fluorescence was noted for the benzofuran-2-yl and pyrrol-2-yl derivatives. Within these series, the highest values were observed for compounds 3f (ca 12600 M -1 ·cm -1 ) and 7h (19200 M -1 ·cm -1 ). The highest overall brightness of the pyrrol-2-yl series was also accomplished by relatively short-wavelength emission, centered at 378-420 nm, whereas the emission of the benzofuran-2-yl series was bathochromically shifted, with the longest maximum at 468 nm for 5f (Figure 2, c) . Solvatochromic nucleoside analogues, i.e., those changing the emission color in response to changes in the polarity of microenvironment, are valuable tools for biophysical studies. 15 We examined the sensitivity of the emission of the synthesized compounds to polarity. The best results were obtained for 4c, which changed the emission wavelength from 419 nm in ethyl acetate to 452 nm in methanol. We expect that the installation of additional electrondonating/withdrawing groups onto this scaffold would further improve the solvatochromism. All the final 6-hetaryl-7-deazapurine bases 3-9 were tested for in vitro cytostatic activities against a panel of cancer and leukemia cell-lines (A549, HCT116, HCT116p53-/-, CCRF-CEM, CEM-DNR, K562 and K562-TAX) but did not show any significant effect at 10 μM concentrations. The lack of activity of the nucleobases (in contrast to the highly potent ribonucleosides 1 and 2) clearly shows that the salvage pathway does not play an important role in the mechanism of action of the deazapurine nucleoside cytostatics 4 and that these modified nucleobases are probably not substrates for phosphoribosyl transferases that would convert them into bioactive nucleotides.
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In conclusion, a library of 57 derivatives of 6-(het)aryl-7-deazapurine bases 3-9, bearing H or F at the 7-position and/or H, F, Cl, Me or NH 2 at the 2-position, was prepared in a single step by aqueous Suzuki-Miyaura cross-coupling reactions of 6-chloro-7-dezapurines 10-15 with a diverse range of (het)arylboronic acids. The hetaryl-modified deazapurine bases all exerted fluorescent properties and we identified several brightly fluorescent compounds as candidates for labelling of nucleic acids. The newly prepared nucleobases 3-9 did not show any significant cytostatic or cytotoxic activities, which provides an important piece of information regarding the SAR and mechanism of action of the parent series of nucleoside cytostatics.
NMR spectra were recorded with 400 MHz ( 1 H at 400 MHz, 13 C at 100.6 MHz) or 500 MHz ( 1 H at 500.0 MHz, 13 C at 125.7 MHz, 19 F at 470.3 MHz) Bruker Avance spectrometers. Melting points were determined with a Kofler block and are uncorrected. Mass spectra were measured using electrospray ionization (ESI) with a LTQ Orbitrap XL (Thermo) for high resolution and with a Qtof micro (Waters) for low resolution. Electron impact (EI) mass spectra were recorded with a GCT Premier (Waters). FTIR spectra were measured with a Bruker Alpha spectrometer using ATR techniques or with a Nicolet Avatar 370 FTIR using the KBr method. 
Suzuki-Miyaura Cross-Coupling; General Procedure
An argon-purged mixture of 4-chloro-7H-pyrrolo [2,3-d] pyrimidine derivative (compounds 10-15, 1 mmol), boronic acid (1.5 mmol), Na 2 CO 3 (318 mg, 3 mmol), Pd(OAc) 2 (11 mg, 0.05 mmol) and TPPTS (71 mg, 0.125 mmol) in H 2 O/MeCN (2:1, 5 mL) was stirred at 100 °C for 3 h. After cooling, the precipitated product was dissolved by stirring with added CH 2 Cl 2 (25 mL) and MeOH (10 mL), and the mixture was loaded onto silica by co-evaporation. Purification by chromatography through a short column of silica (mobile phase is given for individual products) afforded pure solid products, which were crystallized as indicated.
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4-(Thiophen-2-yl)-7H-pyrrolo[2,3-d]pyrimidine (3a)
Compound 3a was prepared from 10 (230 mg, 1.5 mmol) and thiophene-2-boronic acid. Purification using column chromatography (MeOH-CHCl 3, 1%) provided a yellowish solid (262 mg, 87%), which was crystallized from MeOH as needles; mp 240-242 °C; R f = 0.42 (CHCl 3 -MeOH, 10:1). 
IR (ATR
4-(Furan-3-yl)-7H-pyrrolo[2,3-d]pyrimidine (3d)
Compound 3d was prepared from 10 (230 mg, 1.5 mmol) and furan-3-boronic acid as an off-white solid (241 mg, 87%), which was crystallized from MeOH. Column chromatography (MeOH-CHCl 3 , 1%); mp 235-237 °C; R f = 0.39 (CHCl 3 -MeOH, 10:1). 
IR (ATR)
:
4-(Benzofuran-2-yl)-7H-pyrrolo[2,3-d]pyrimidine (3f)
Compound 3f was prepared from 10 (153.5 mg, 1 mmol) and benzofuran-2-boronic acid as a yellow solid (215 mg, 91%) after crystallization from MeOH. Column chromatography (MeOH-CHCl 3 , 1%); mp 270-272 °C; R f = 0.42 (CHCl 3 -MeOH, 10:1). 
IR (ATR)
4-(1H-Pyrrol-2-yl)-7H-pyrrolo[2,3-d]pyrimidine (3h)
Compound 3h was prepared from 10 (153.5 mg, 1 mmol) and N-Bocpyrrole-2-boronic acid as a greenish solid (129 mg, 70%), which was crystallized from MeOH-CHCl 3 . Column chromatography (MeOH- 
4-(1H-Pyrrol-3-yl)-7H-pyrrolo[2,3-d]pyrimidine (3i)
Compound 3i was prepared from 10 (153.5 mg, 1 mmol) and 1-(triisopropylsilyl)-1H-pyrrole-3-boronic acid as a greenish solid (78 mg, 42%), which was crystallized from water. Column chromatography 
5-Fluoro-4-(thiophen-2-yl)-7H-pyrrolo[2,3-d]pyrimidine (4a)
Compound 4a was prepared from 11 (172 mg, 1 mmol) and thiophene-2-boronic acid as a brownish solid (165 mg, 75%), which was crystallized from MeOH-H 2 O. Column chromatography (MeOH-CHCl 3 , 1%); mp 278-279 °C; R f = 0.38 (CHCl 3 -MeOH, 10:1). 
IR (KBr
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5-Fluoro-4-(thiophen-3-yl)-7H-pyrrolo[2,3-d]pyrimidine (4b)
Compound 4b was prepared from 11 (172 mg, 1 mmol) and thiophene-3-boronic acid as a brownish solid (170 mg, 72%), which was crystallized from MeOH-H 2 
5-Fluoro-4-(furan-2-yl)-7H-pyrrolo[2,3-d]pyrimidine (4c)
Compound 4c was prepared from 11 (172 mg, 1 mmol) and furan-2-boronic acid as a brownish solid (140 mg, 69%), which was crystal- 
5-Fluoro-4-(1H-pyrrol-3-yl)-7H-pyrrolo[2,3-d]pyrimidine (4i)
Compound 4i was prepared from 11 (172 mg, 1 mmol) and 1-(triisopropylsilyl)-1H-pyrrole-3-boronic acid as a brownish solid (75 mg, 35%), which was crystallized from MeOH-H 2 O. 
2-Amino-4-(thiophen-2-yl)-7H-pyrrolo[2,3-d]pyrimidine (5a)
Compound 5a was prepared from 12 (337 mg, 2 mmol) and thiophene-2-boronic acid as a yellowish solid (370 mg, 86%), which was crystallized from MeOH- 
2-Amino-4-(thiophen-3-yl)-7H-pyrrolo[2,3-d]pyrimidine (5b)
Compound 5b was prepared from 12 (253 mg, 1.5 mmol) and thiophene-3-boronic acid as a yellowish solid (290 mg, 90%), which was crystallized from MeOH- 
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2-Amino-4-(furan-2-yl)-7H-pyrrolo[2,3-d]pyrimidine (5c)
Compound 5c was prepared from 12 (253 mg, 1.5 mmol) and furan-2-boronic acid as a yellowish solid (190 mg, 67%), which was crystallized from MeOH-H 2 
2-Amino-4-(furan-3-yl)-7H-pyrrolo[2,3-d]pyrimidine (5d)
Compound 5d was prepared from 12 (253 mg, 1.5 mmol) and furan-3-boronic acid as a yellowish solid (250 mg, 83%), which was crystal- 
2-Amino-4-phenyl-7H-pyrrolo[2,3-d]pyrimidine (5e)
Compound 5e was prepared from 12 (253 mg, 1.5 mmol) and phenylboronic acid as a yellowish solid (250 mg, 80%), which was crystal- -4-(benzofuran-2-yl)-7H-pyrrolo[2,3-d]pyrimidine (5f) Compound 5f was prepared from 12 (337 mg, 2 mmol) and benzofuran-2-boronic acid as a yellowish solid (290 mg, 58%), which was crystallized from MeOH- -4-(1H-pyrrol-2-yl)-7H-pyrrolo[2,3-d 
2-Amino
2-Amino-4-(1H-pyrrol-3-yl)-7H-pyrrolo[2,3-d]pyrimidine (5i)
Compound 5i was prepared from 12 (253 mg, 1. 
2-Methyl-4-(thiophen-2-yl)-7H-pyrrolo[2,3-d]pyrimidine (6a)
Compound 6a was prepared from 13 (168 mg, 1 mmol) and thiophene-2-boronic acid as a yellowish solid (205 mg, 95%), which was crystallized from MeOH- 
2-Methyl-4-(thiophen-3-yl)-7H-pyrrolo[2,3-d]pyrimidine (6b)
Compound 6b was prepared from 13 (168 mg, 1 mmol) and thiophene-3-boronic acid as a white solid (188 mg, 87%), which was crystallized from MeOH 
4-(Furan-2-yl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidine (6c)
Compound 6c was prepared from 13 (168 mg, 1 mmol) and furan-2-boronic acid as a yellowish solid (125 mg, 63%), which was crystal- 
2-Fluoro-4-(thiophen-2-yl)-7H-pyrrolo[2,3-d]pyrimidine (7a)
Compound 7a was prepared from 14 (172 mg, 1 mmol) and thiophene-2-boronic acid as a yellowish solid (145 mg, 66%), which was crystallized from MeOH-H 2 O. Column chromatography (EtOAc-CH 2 
